Brief: Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Senti-202
11/02/2026 14:03
Feb 11 (Reuters) - Senti Biosciences Inc SNTI.O: SENTI BIOSCIENCES COMPLETES ENROLLMENT IN PHASE 1 CLINICAL TRIAL OF SENTI-202 FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML) Source text: ID:nGNX9mWWcd Further company coverage: SNTI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Senti Biosciences Holdings
See all newsBrief: Senti Biosciences Says Offering 15.97 Million Shares Of Common Stock For Resale By Selling Securityholder
Senti Biosciences Q1 net loss narrows on cost reduction
Brief: Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy
Brief: Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC Filing
Senti Biosciences Q4 revenue misses analyst estimates